Symphony Buys ImpactRx

In the US, private equity firm Symphony Technology Group (STG) - the parent of retail market intelligence giant SymphonyIRI - has acquired a majority interest in physician panel provider ImpactRx. Financial terms of the transaction were not disclosed.

Mount Laurel, NJ-based ImpactRx - which is part-owned by Merck Capital Ventures, the venture capital arm of Merck - uses proprietary panels, custom research and analytics to measure the impact of pharma promotion on physicians' prescribing behaviour. STG MD J.T. Treadwell described the acquisition as a 'terrific starting point' for investment in the life sciences sector.

Under the terms of the agreement, ImpactRx will operate as an independent STG portfolio company, under the leadership of current President and CEO Richard Altus (pictured).

'STG will help ImpactRx to improve as a leader in evaluating and interpreting the drivers of physician behavior,' Altus commented. 'In addition, integrating our syndicated data with STG's vast data modeling and analytics expertise, will enable us to deliver the solutions our clients need to grow their businesses in today's complicated and competitive biopharmaceutical marketplace.'

Last week, STG launched an ad performance analytics arm called SymphonyAM, supported by the acquisition of ad effectiveness measurement firm Factor Technology Group (FactorTG).

Web sites: www.symphonytg.com and www.impactrx.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Information Resources
• All news